Investment Counsel Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,440 shares of the company’s stock after selling 550 shares during the quarter. Johnson & Johnson comprises about 3.8% of Investment Counsel Inc.’s investment portfolio, making the stock its 3rd biggest holding. Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $4,556,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the business. Sanders Capital LLC increased its stake in Johnson & Johnson by 2.8% in the 2nd quarter. Sanders Capital LLC now owns 4,476,132 shares of the company’s stock worth $653,107,000 after purchasing an additional 122,500 shares in the last quarter. Compass Capital Management Inc. increased its stake in Johnson & Johnson by 0.4% in the 2nd quarter. Compass Capital Management Inc. now owns 184,154 shares of the company’s stock worth $24,362,000 after purchasing an additional 659 shares in the last quarter. Alpha Cubed Investments LLC increased its stake in Johnson & Johnson by 18.6% in the 2nd quarter. Alpha Cubed Investments LLC now owns 108,720 shares of the company’s stock worth $14,383,000 after purchasing an additional 17,022 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in Johnson & Johnson by 0.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after purchasing an additional 3,533 shares in the last quarter. Finally, Loeb Partners Corp increased its stake in Johnson & Johnson by 29.4% in the 2nd quarter. Loeb Partners Corp now owns 46,700 shares of the company’s stock worth $6,178,000 after purchasing an additional 10,600 shares in the last quarter. Hedge funds and other institutional investors own 66.06% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) is Investment Counsel Inc.’s 3rd Largest Position” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2017/10/30/johnson-johnson-jnj-is-investment-counsel-inc-s-3rd-largest-position.html.
A number of equities analysts recently weighed in on the company. J P Morgan Chase & Co lifted their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 16th. Vetr raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price on the stock in a research note on Monday. BTIG Research cut Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price on the stock. in a research note on Friday, July 21st. UBS AG reaffirmed a “buy” rating and set a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $135.00 target price (up previously from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Four analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $143.70.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 141.78 on Monday. The firm has a market capitalization of $380.54 billion, a price-to-earnings ratio of 24.66 and a beta of 0.78. The stock’s 50 day moving average price is $135.26 and its 200 day moving average price is $131.38. Johnson & Johnson has a one year low of $109.32 and a one year high of $144.35.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $1.68 earnings per share. Analysts expect that Johnson & Johnson will post $7.28 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.37%. Johnson & Johnson’s payout ratio is presently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.